Bayer and Hologic collaborate to deliver contrast-enhanced-mammography solutions to improve the detection of breast cancer
Bayer and Hologic, Inc., announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions
CEM is an innovative highly sensitive and low-cost breast imaging modality which combines digital mammography with the administration of a contrast agent to support breast cancer diagnosis and guide treatment decisions. The partnership brings together the companies’ leading technologies (Hologic mammography gantries and Bayer CEM approved injection systems), which enable accurate administration of contrast media during a mammography examination. Bayer and Hologic aim to optimally support radiologists and their teams to effectively implement CEM seamlessly into a radiologist’s workflow.
Related news and insights
Roche announced the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc., a privately owned US company based in Berkeley, California. Carmot’s R&D portfolio includes clinical stage subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes, as well as a number of preclinical programs
Johnson & Johnson MedTech announced the completion of the acquisition of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib)
AbbVie Inc.and ImmunoGen, Inc. announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC)